Medical Advocates
Adefovir Dipivoxil (Hepsera)
 
HBV Journal Abstracts, Posters, and
Commentaries

General Reports
 Resistance
 Drug/Drug Interactions
 Diagnostics/Monitoring
Efficacy
 Transplants



 
Adefovir Journal Citations Main Page Main New/Newsworthy  Home Page      
Last Update:  January 26, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
                
 
Adefovir serum levels do not differ between responders and nonresponders.
 Deterding K, Naesens L, Buti M, et al
J Viral Hepat. 2011 Jul;18(7):e175-8.
Abstract

Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C
virus eradication in hepatitis B and C virus carriers.
Renou C, Cadranel JF, Pariente A, et al  
Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1235-7.
 Abstract
 
Efficacy and safety of adefovir dipivoxil 20mg daily in HBeAg-positive patients with lamivudine-
resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10mg daily.
 Hezode C, Chevaliez S, Bouvier-Alias M, et al 
J Hepatol. 2007 Feb 9;|
 Abstract
 
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative
chronic hepatitis B.
 Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.
Hepatology. 2007 Jan 26;45(2):307-313
Abstract
 
Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype
C infection.
 Kim do Y, Kim HJ, Lee CK, et al  
Liver Int. 2007 Feb;27(1):47-53.
 Abstract
 
FULL-TEXT ARTICLE
 Successful Treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed
under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with
YMDD mutations.
 Cakir N, Pamuk ON, Umit H, Midilli K. 
Intern Med. 2006;45(21):1213-5.
 Paper
 
A double-blind, randomized, lamivudine-controlled clinical trial of DAIDINGTM (adefovir dipivoxil)
for lamivudine-resistant patients with chronic hepatitis B
 ang YM, Chen YK, Zhang DZ, et al
Zhonghua Gan Zang Bing Za Zhi. 2006 Nov;14(11):803-5
 Abstract
 
Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis.
 Grattagliano I, Palmieri VO, Portincasa P, Palasciano G.  
Ann Pharmacother. 2006 Sep;40(9):1681-4.
Abstract
 
The change of HBV nucleotide sequence during Adefovir dipivoxil treatment.
Lu JX, Xie DY, Xu QH
Zhonghua Gan Zang Bing Za Zhi. 2006 May;14(5):331-6.
 Abstract
 
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations
in patients with liver cirrhosis.
 Liaw YF, Lee CM, Chien RN, Yeh CT. 
J Viral Hepat. 2006 Apr;13(4):250-5.
 Abstract
 
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Zhang WX, Lai V, Mutimer D, Mirza D.
Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):154-6
 Abstract
 
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant
hepatitis B and HIV-1.
 Benhamou Y, Thibault V, Vig P, et al  
 J Hepatol. 2006 Jan;44(1):62-7
 Abstract
 
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic
resistance to lamivudine.
Lampertico P, Vigano M, Manenti E, et al 
Hepatology. 2005 Dec;42(6):1414-9.
 Abstract
 
Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated
Liver Disease and Lamivudine-resistant Hepatitis B Virus.
 Kim KM, Choi WB, Lim YS, et al 
J Korean Med Sci. 2005 Oct;20(5):821-8.
 Abstract
 
Adefovir dipivoxil-a new effective treatment for chronic infection with hepatitits B virus.
Husa P. 
Klin Mikrobiol Infekc Lek. 2005 Sep;11(4):119-122.
Abstract
 
Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine
combination therapy.
Mihm U, Gartner BC, Faust D, et aL
J Hepatol. 2005 Jun 15;
Abstract
 
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant
hepatitis B e antigen-negative chronic hepatitis B.
 Vassiliadis T, Nikolaidis N, Giouleme O 
Aliment Pharmacol Ther. 2005 Mar 1;21(5):531-7.
 Abstract
 
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy
for lamivudine failure.
Maynard M, Parvaz P, Durantel S, et al
J Hepatol. 2005 Feb;42(2):279-81.
 Abstract

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in
patients.
Westland CE, Yang H, Delaney WE 4th 
J Viral Hepat. 2005 Jan;12(1):67-73.
 Abstract
 
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind,
randomized, placebo-controlled studies.
Izzedine H, Hulot JS, Launay-Vacher V, et al
 Kidney Int. 2004 Sep;66(3):1153-8.
 Abstract
 
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil
therapy.
 Werle B, Cinquin K, Marcellin P. et al 
Viral Hepat. 2004 Jan;11(1):74-83.
 Abstract
 
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-
resistant chronic hepatitis B.
 Peters MG, Hann Hw H, Martin P, et al.
Gastroenterology. 2004 Jan;126(1):91-101
 Abstract
 
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant
hepatitis B virus.
 Perrillo R, Hann HW, Mutimer D,et al  
Gastroenterology. 2004 Jan;126(1):81-9
 Abstract
 
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir
in treatment of DNA virus and retrovirus infections.
De Clercq E.
Clin Microbiol Rev. 2003 Oct;16(4):569-96.
 Abstract 
 
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for
chronic hepatitis B.
Westland CE, Yang H, Delaney WE 4th,
Hepatology. 2003 Jul;38(1):96-103.
Abstract

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P, Chang TT, Lim SG, et al.
N Engl J Med 2003 Feb 27;348(9):808-16
 Abstract

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al  
 N Engl J Med 2003 Feb 27;348(9):800-7
 Abstract

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B
virus infection model.
 Le Guerhier F, Thermet A, Guerret S, et al.
J Hepatol 2003 Mar;38(3):328-34
 Abstract

Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient
with cirrhosis and renal insufficiency.
Tillmann HL, Bock CT, Bleck JS
Liver Transpl 2003 Feb;9(2):191-6
 Abstract

Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus
DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.
 Birkus G, Gibbs CS, Cihlar T.  
 J Viral Hepat 2003 Jan;10(1):50-54
 Abstract

Predominance of pre-S1 mutated hepatitis B virus in a patient following treatment with
adefovir dipivoxil.
Villa E, Boarino V, Grottola A, , et al.
Liver Transpl 2003 Feb;9(2):188-90
 Abstract
 
Treatment of HBeAg-Negative Chronic Hepatitis B.
 Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D.   
 Semin Liver Dis 2003;23(1):81-8
 Abstract

A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection:
the ADHOC trial.
ADHOC International Steering Committee.
HIV Med 2002 Oct;3(4):229-38
 Abstract

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and
lamivudine resistant hepatitis B virus.
Walsh KM, Woodall T, Lamy P, et al. 
Gut 2001 Sep;49(3):436-440
 Abstract

 FULL TEXT ARTICLE
 In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine,and
Adefovir.
Colledge D, Civitico G, Locarnini S, Shaw T.
Antimicrob Agents Chemother 2000 Mar;44(3):551-560
 Paper
 
Resistance
                
 
HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C, and D.
 Liu Y, Miller MD, Kitrinos KM.
Liver Int. 2013 Oct 1.
 Abstract

The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of
hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy.
 Qin YL, Zhang JM, Huang YX, et al  
Zhonghua Gan Zang Bing Za Zhi. 2007 Jan;15(1):4-7
 Abstract
 
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B
after 48 weeks of adefovir dipivoxil monotherapy.
 Lee YS, Suh DJ, Lim YS, et al
Hepatology. 2006 Jun;43(6):1385-91.
Abstract

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after
48 weeks of adefovir dipivoxil monotherapy.
 Lee YS, Suh DJ, Lim YS, et al 
Hepatology. 2006 May 25;43(6):1385-1391
 Abstract

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.
Fung SK, Andreone P, Han SH, et al  
 J Hepatol. 2005 Dec;43(6):937-43.
 Abstract

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B
 treated with adefovir.
Sheldon JA, Corral A, Rodes B, et al 
AIDS. 2005 Nov 18;19(17):2036-8.
Abstract
 
  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic
decompensation.
Fung SK, Andreone P, Han SH, et al 
J Hepatol. 2005 Sep 14;
Abstract
 
  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance
to both lamivudine and adefovir.
 Brunelle MN, Jacquard AC, Pichoud C  
Hepatology. 2005 May 24;41(6):1391-1398
 Abstract
 
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation
in the HBV polymerase.
Angus P, Vaughan R, Xiong S, et al.
Gastroenterology. 2003 Aug;125(2):292-7.
Abstract
 

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up
to 60 weeks.
Yang H, Westland CE, Delaney WE 4th,  et al.
Hepatology 2002 Aug;36(2):464-73
 Abstract

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (-)-beta-
D-26-Diaminopurine Dioxolane and 2'-Fluoro-5-Methyl-beta-L-Arabinofuranosyluracil.
Chin R, Shaw T, Torresi J, Sozzi V,  et al.
Antimicrob Agents Chemother 2001 Sep;45(9):2495-2501
 Abstract
Drug/Drug Interactions
                
  Absence of a Pharmacokinetic Interaction Between Entecavir and Adefovir.
 Bifano M, Yan JH, Smith RA. et al
J Clin Pharmacol. 2007 Aug 3;
 Abstract
Diagnostics/Monitoring
                
  Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant
strains and comparison with direct sequencing and line probe assays.
Lupo J, Larrat S, Hilleret MN, Germi R, et al
J Virol Methods. 2008 Nov 25
 Abstract
Efficacy
                
Adefovir dipivoxil/Emtricitabine
 
  96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil
monotherapy in the treatment of chronic hepatitis B.
 Hui CK, Zhang HY, Bowden S, et al 
J Hepatol. 2007 Dec 31
 Abstract

Adefovir dipivoxil/Pegylated interferon alfa-2a
 
 
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a
for the treatment of chronic hepatitis B.
 Takeda A, Jones J, Shepherd J, et al
J Viral Hepat. 2007 Feb;14(2):75-88.
Abstract

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a
systematic review and economic evaluation.
 Shepherd J, Jones J, Takeda A, Davidson P, Price A. 
Health Technol Assess. 2006 Aug;10(28):1-200.
 Abstract
Transplantation
                
 
Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to
lamivudine-resistant hepatitis B.
 Tse KC, Yap DY, et al
Clin Transplant. 2009 Sep 16
 Abstract

Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus
infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M, Karasu Z, Zeytunlu M, et al  
J Gastroenterol Hepatol. 2007 Dec;22(12):2130-4.
Abstract
 
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-
on adefovir dipivoxil plus lamivudine.
 Lo CM, Liu CL, Lau GK, et al .
 Liver Transpl. 2005 Jun 22;11(7):807-813
Abstract
 
Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant
Hepatitis B Virus.
Herreros de Tejada Echanojauregui A  
Transplant Proc. 2005 Apr;37(3):1507-1508
 Abstract

Therapeutic Effect of Adefovir Dipivoxil on Recurrent or de novo Infection of Hepatitis
B Virus after Liver Transplantation: A Preliminary Report.
Kim KK, Kim KH, Hwang S, Ahn CS,
Korean J Gastroenterol. 2005 Mar;45(3):174-80.
 Abstract

Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with
lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and
hepatitis B immunoglobulin.
 Lo CM, Cheung ST, Ng IO, et al  
Liver Transpl. 2004 Apr;10(4):557-63.
 Abstract

Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver
transplantation.
Toniutto P, Fumo E, Caldato M, et al
 Transplantation. 2004 Feb 15;77(3):472-3.
 Abstract
   
 
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver
transplantation patients.
 Schiff ER, Lai CL, Hadziyannis S, et al.  
Hepatology. 2003 Dec;38(6):1353-5
 Abstract 

Prevention of and treatment for hepatitis B virus infection after liver transplantation in the
nucleoside analogues era.
Papatheodoridis GV, Sevastianos V, Burroughs AK. et al
Am J Transplant 2003 Mar;3(3):250-8
Abstract

Adefovir Journal Citations Main Page Main New/Newsworthy  Home Page      

Adefovir Dipivoxil HBV Journal Citations